Oragenics (OGEN) issues Q3 2025 developments update press release

Rhea-AI Filing Summary

Oragenics, Inc. filed a current report to note that it has issued a new press release for shareholders. On November 12, 2025, the company released an update describing recent developments that took place during the third quarter of 2025 and shortly afterward. The report states that this press release is being furnished as an exhibit and incorporated by reference, directing readers to that document for the detailed business and operational update.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false 0001174940 0001174940 2025-11-12 2025-11-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934.

Date of Report: November 12, 2025

(Date of earliest event reported)

Oragenics, Inc.

(Exact name of registrant as specified in its charter)

FL		001-32188		59-3410522
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification Number)

1990 Main Street Suite 750 Sarasota, FL		34236
(Address of principal executive offices)		(Zip Code)

813-286-7900

(Registrant’s telephone number, including area code)

(Former Name or Former Address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock		OGEN		NYSE American

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

ITEM 8.01. OTHER INFORMATION.

On November 12, 2025, Oragenics, Inc. (the “Company”) issued a press release updating the Company’s shareholders on recent Company developments that have occurred in the third quarter of 2025 and shortly thereafter. A copy of the Press Release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release dated November 12, 2025.
104		Cover page Interactive Data File (embedded in the cover page formatted in Inline XBRL)

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 12^th day of November 2025.

	ORAGENICS, INC. (Registrant)
	BY:	/s/ Janet Huffman
		Janet Huffman
		Chief Executive Officer

FAQ

What did Oragenics (OGEN) disclose in this 8-K filing?

Oragenics, Inc. disclosed that it issued a press release on November 12, 2025 providing an update to shareholders on recent company developments from the third quarter of 2025 and shortly thereafter.

Which item of Form 8-K did Oragenics (OGEN) use for this disclosure?

Oragenics used Item 8.01 – Other Information to report that it had issued a shareholder update press release.

Does the Oragenics (OGEN) 8-K include the full text of the shareholder update?

The 8-K states that the shareholder update is contained in a press release, which is attached as Exhibit 99.1 and incorporated by reference.

What exhibit is attached to the Oragenics (OGEN) 8-K filing?

The filing lists Exhibit 99.1 as a press release dated November 12, 2025, and Exhibit 104 as the cover page Interactive Data File in Inline XBRL format.

Who signed the November 12, 2025 Oragenics (OGEN) 8-K?

The 8-K was signed on behalf of Oragenics, Inc. by Janet Huffman, who is identified as the company’s Chief Executive Officer.

What period do the developments in the Oragenics (OGEN) press release cover?

The filing notes that the press release updates shareholders on company developments that occurred in the third quarter of 2025 and shortly thereafter.